| 1 | Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia or Pneumonia | 5.6 | 3 | Citations (PDF) |
| 2 | Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis | 4.3 | 0 | Citations (PDF) |
| 3 | Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections | 4.1 | 0 | Citations (PDF) |
| 4 | Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors? | 4.3 | 0 | Citations (PDF) |
| 5 | Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185 | 4.5 | 5 | Citations (PDF) |
| 6 | Differential <i>in vitro</i> susceptibility to ampicillin/ceftriaxone combination therapy among <i>Enterococcus faecalis</i> infective endocarditis clinical isolates | 3.2 | 1 | Citations (PDF) |
| 7 | Bacteriophage and antibiotic combination therapy for recurrent
<i>Enterococcus faecium</i>
bacteremia | 4.5 | 7 | Citations (PDF) |
| 8 | Development of Predictive Models to Inform a Novel Risk Categorization Framework for Antibiotic Resistance in <i>Escherichia coli–</i>Caused Uncomplicated Urinary Tract Infection | 5.6 | 0 | Citations (PDF) |
| 9 | Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres | 2.2 | 2 | Citations (PDF) |
| 10 | Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia | 3.2 | 0 | Citations (PDF) |
| 11 | Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia | 3.2 | 3 | Citations (PDF) |
| 12 | Clinical manifestations and treatment outcomes for patients with <i>Pseudomonas</i> endocarditis | 3.2 | 1 | Citations (PDF) |
| 13 | Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis | 4.4 | 0 | Citations (PDF) |
| 14 | Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing <i>Escherichia coli</i> bloodstream isolate exhibiting reduced susceptibility to both agents at baseline | 1.8 | 0 | Citations (PDF) |
| 15 | Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant <i>Acinetobacter baumannii</i> infections | 1.8 | 0 | Citations (PDF) |
| 16 | Molecular characterization of clinically isolated
<i>Pseudomonas aeruginosa</i>
with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021 | 4.3 | 1 | Citations (PDF) |
| 17 | Rapid molecular testing is associated with decreased broad-spectrum antibiotic use among patients with streptococcal bloodstream infections | 0.7 | 0 | Citations (PDF) |
| 18 | Early initiation of three-drug combinations for the treatment of carbapenem-resistant <i>A. baumannii</i> among COVID-19 patients | 3.2 | 12 | Citations (PDF) |
| 19 | Epidemiology and Clinical Outcomes of Non-HACEK Gram-Negative Infective Endocarditis | 0.8 | 9 | Citations (PDF) |
| 20 | Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug‐resistant <i>Burkholderia multivorans</i> | 2.2 | 18 | Citations (PDF) |
| 21 | Impact of<i>ompk36</i>genotype and KPC subtype on the<i>in vitro</i>activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing<i>K. pneumoniae</i>clinical isolates | 1.8 | 5 | Citations (PDF) |
| 22 | <i>Antimicrobial Agents and Chemotherapy</i>
Launches a New Section Focused on Innovative Antimicrobial Stewardship Studies | 4.3 | 0 | Citations (PDF) |
| 23 | Carbonic Anhydrase Inhibition as a Target for Antibiotic Synergy in Enterococci | 3.6 | 9 | Citations (PDF) |
| 24 | Impact of Rapid Identification and Stewardship Intervention on Coagulase-Negative <i>Staphylococcus</i> Bloodstream Infection | 0.8 | 3 | Citations (PDF) |
| 25 | High-level ceftazidime/avibactam resistance in<i>Escherichia coli</i>conferred by the novel plasmid-mediated β-lactamase CMY-185 variant | 3.2 | 10 | Citations (PDF) |
| 26 | <i>Serratia</i> endocarditis: antimicrobial management strategies and clinical outcomes | 3.2 | 3 | Citations (PDF) |
| 27 | Mutations in <i>ompK36</i> differentially impact <i>in vitro</i> synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing <i>Klebsiella pneumoniae</i> | 1.8 | 4 | Citations (PDF) |
| 28 | <i>In vitro</i> activity of cefiderocol against <i>Pseudomonas aeruginosa</i> demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors | 1.8 | 13 | Citations (PDF) |
| 29 | Stewardship-Guided T2Candida Testing Shortens Time to Antifungal Treatment and Reduces Antifungal Usage Among Medical Intensive Care Unit Patients With Septic Shock | 0.8 | 2 | Citations (PDF) |
| 30 | Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients | 5.6 | 22 | Citations (PDF) |
| 31 | Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis | 1.5 | 3 | Citations (PDF) |
| 32 | Hydrolytic activity of KPC-producing <i>Klebsiella pneumoniae</i> clinical isolates | 1.7 | 2 | Citations (PDF) |
| 33 | Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials | 2.1 | 46 | Citations (PDF) |
| 34 | Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies | 5.6 | 60 | Citations (PDF) |
| 35 | Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia | 5.6 | 28 | Citations (PDF) |
| 36 | Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam | 4.3 | 32 | Citations (PDF) |
| 37 | Convergent Evolution of Antibiotic Tolerance in Patients with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia | 2.8 | 14 | Citations (PDF) |
| 38 | Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC β-Lactamase | 4.3 | 15 | Citations (PDF) |
| 39 | Isolation and Characterization of Lytic Bacteriophages Targeting Diverse <i>Enterobacter</i> spp. Clinical Isolates | 1.2 | 3 | Citations (PDF) |
| 40 | Within-Host Genotypic and Phenotypic Diversity of Contemporaneous Carbapenem-Resistant Klebsiella pneumoniae from Blood Cultures of Patients with Bacteremia | 4.5 | 7 | Citations (PDF) |
| 41 | Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017 | 5.6 | 48 | Citations (PDF) |
| 42 | Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections | 5.6 | 37 | Citations (PDF) |
| 43 | Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients | 5.6 | 43 | Citations (PDF) |
| 44 | <i>In Vitro</i>
Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam | 4.3 | 44 | Citations (PDF) |
| 45 | In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii | 4.2 | 22 | Citations (PDF) |
| 46 | Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists | 4.4 | 40 | Citations (PDF) |
| 47 | Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices | 0.8 | 1 | Citations (PDF) |
| 48 | <i>In Vitro</i>
Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA | 3.6 | 36 | Citations (PDF) |
| 49 | Sequence type-258 carbapenem-resistant Klebsiella pneumoniae isolates in which ceftazidime–avibactam resistance emerged are not hypermutators | 1.7 | 1 | Citations (PDF) |
| 50 | Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase–Producing Gram-Negative Bacteria? | 5.6 | 50 | Citations (PDF) |
| 51 | Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections | 5.6 | 73 | Citations (PDF) |
| 52 | Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis | 4.1 | 23 | Citations (PDF) |
| 53 | Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube | 3.2 | 13 | Citations (PDF) |
| 54 | Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in
<i>Enterobacter cloacae</i>
Due to AmpC R2 Loop Deletion | 4.3 | 61 | Citations (PDF) |
| 55 | Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients | 4.3 | 22 | Citations (PDF) |
| 56 | Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data? | 4.3 | 15 | Citations (PDF) |
| 57 | Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible
<i>Citrobacter</i>
spp. at a Tertiary Health Care Center over 2 Decades | 4.1 | 24 | Citations (PDF) |
| 58 | Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in <i>Enterobacter cloacae</i> Complex Following Exposure to Cefepime | 5.6 | 64 | Citations (PDF) |
| 59 | Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Meningitis | 0.8 | 11 | Citations (PDF) |
| 60 | Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature | 1.7 | 26 | Citations (PDF) |
| 61 | Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility | 4.3 | 20 | Citations (PDF) |
| 62 | Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for
<i>FKS</i>
-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis | 4.3 | 6 | Citations (PDF) |
| 63 | High-Level Carbapenem Resistance in OXA-232-Producing Raoultella ornithinolytica Triggered by Ertapenem Therapy | 4.3 | 12 | Citations (PDF) |
| 64 | Evolution of Outbreak-Causing Carbapenem-Resistant Klebsiella pneumoniae ST258 at a Tertiary Care Hospital over 8 Years | 4.5 | 54 | Citations (PDF) |
| 65 | Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258 | 3.2 | 5 | Citations (PDF) |
| 66 | Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of
<i>Klebsiella pneumoniae</i>
in a Hollow Fiber Infection Model | 4.3 | 14 | Citations (PDF) |
| 67 | Effects of KPC Variant and Porin Genotype on the
<i>In Vitro</i>
Activity of Meropenem-Vaborbactam against Carbapenem-Resistant
<i>Enterobacteriaceae</i> | 4.3 | 62 | Citations (PDF) |
| 68 | Spontaneous Mutational Frequency and
<i>FKS</i>
Mutation Rates Vary by Echinocandin Agent against
<i>Candida glabrata</i> | 4.3 | 35 | Citations (PDF) |
| 69 | Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients | 5.6 | 50 | Citations (PDF) |
| 70 | Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections | 4.3 | 221 | Citations (PDF) |
| 71 | Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa | 4.1 | 49 | Citations (PDF) |
| 72 | 1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa | 0.8 | 13 | Citations (PDF) |
| 73 | 2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance | 0.8 | 1 | Citations (PDF) |
| 74 | 2421. Tedizolid Is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses | 0.8 | 0 | Citations (PDF) |
| 75 | 1064. Clinical Outcomes of Daptomycin in Combination With Ceftaroline or Anti-Staphylococcal Penicillins for Patients With Persistent MRSA Bacteremia | 0.8 | 0 | Citations (PDF) |
| 76 | 1528. A Real-World Perspective on Treatment of CRE UTIs With Oral Agents | 0.8 | 0 | Citations (PDF) |
| 77 | 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia | 0.8 | 0 | Citations (PDF) |
| 78 | 2420. A Real-World Perspective on the Efficacy of Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infections | 0.8 | 1 | Citations (PDF) |
| 79 | 247. Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria | 0.8 | 0 | Citations (PDF) |
| 80 | 357. Aspergillus Isolates Remain Largely Susceptible to Azoles and Other Antifungals at a Large Transplant Program Using Azole Prophylaxis | 0.8 | 0 | Citations (PDF) |
| 81 | 706. Ceftazidime-Avibactam (CZA) and Meropenem (MER) Are Synergistic and Bactericidal Against Genetically Diverse KPC-Producing Klebsiella pneumoniae (Kp) | 0.8 | 0 | Citations (PDF) |
| 82 | 2033. Incorporating T2Candida Testing into Rational Antifungal (AF) Management: A Successful Pilot Study of Diagnostic Stewardship (DS) Directed Toward Specific Intensive Care Unit (ICU) Patients At-Risk for Sepsis due to Invasive Candidiasis (IC) | 0.8 | 1 | Citations (PDF) |
| 83 | Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients | 4.3 | 31 | Citations (PDF) |
| 84 | Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance | 4.3 | 28 | Citations (PDF) |
| 85 | Mutations in
<i>bla</i>
<sub>KPC-3</sub>
That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases | 4.3 | 160 | Citations (PDF) |
| 86 | <i>In Vitro</i>
Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases | 4.3 | 88 | Citations (PDF) |
| 87 | Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β-Lactams for Major Gram-Negative Bacterial Pathogens | 5.6 | 51 | Citations (PDF) |
| 88 | Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae | 4.3 | 114 | Citations (PDF) |
| 89 | Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia | 4.3 | 373 | Citations (PDF) |
| 90 | Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance | 5.6 | 233 | Citations (PDF) |
| 91 | Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
<i>bla</i>
<sub>KPC-3</sub>
Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections | 4.3 | 344 | Citations (PDF) |
| 92 | <i>Klebsiella pneumoniae</i>
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering | 4.5 | 101 | Citations (PDF) |
| 93 | Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients | 4.3 | 38 | Citations (PDF) |
| 94 | Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure | 4.3 | 77 | Citations (PDF) |
| 95 | Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature | 0.8 | 105 | Citations (PDF) |
| 96 | Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center | 0.8 | 0 | Citations (PDF) |
| 97 | Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users | 0.8 | 43 | Citations (PDF) |
| 98 | Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria | 2.5 | 46 | Citations (PDF) |
| 99 | Outcomes of Candida Empyema Correlate with Source of Infection | 0.8 | 0 | Citations (PDF) |
| 100 | Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies | 3.6 | 10 | Citations (PDF) |
| 101 | Outcomes Comparing Initial Fluconazole to Micafungin in ICU Patients with Candidemia | 0.8 | 0 | Citations (PDF) |
| 102 | Retrospective Study of Outcomes Comparing Initial Treatment with Fluconazole or Micafungin in Immunosuppressed Patients with Candidemia | 0.8 | 0 | Citations (PDF) |
| 103 | Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment | 2.5 | 115 | Citations (PDF) |
| 104 | Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy (OPAT) Program Failure Among Intravenous Drug Users (IVDUs) | 0.8 | 2 | Citations (PDF) |
| 105 | Daptomycin Non-susceptible VRE: Problematic Pathogen or Misclassified Microbe? | 0.8 | 0 | Citations (PDF) |
| 106 | Impact of Rectal Colonization With Highly Drug-Resistant Enterobacteriaceae on Post-Transplant Infections: The Carbapenem-Resistant Enterobacteriaceae Carriage in Solid Organ Transplant (CREST) Study | 0.8 | 0 | Citations (PDF) |
| 107 | Rapid Emergence of Ceftazidime-Avibactam Resistance Due to blaKPC-3 Mutations During Treatment (tx) of Carbapenem-Resistant Klebsiella pneumoniae (CRKp) Infections | 0.8 | 1 | Citations (PDF) |
| 108 | Emerging Waves of Carbapenem Resistance Among Gram-Negative Pathogens at a Tertiary Center | 0.8 | 0 | Citations (PDF) |
| 109 | Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis | 4.3 | 14 | Citations (PDF) |
| 110 | Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae | 4.3 | 39 | Citations (PDF) |
| 111 | Rapid Detection of
<i>FKS</i>
-Associated Echinocandin Resistance in Candida glabrata | 4.3 | 51 | Citations (PDF) |
| 112 | Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study: Table 1. | 3.2 | 13 | Citations (PDF) |
| 113 | Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1. | 5.6 | 370 | Citations (PDF) |
| 114 | Adverse Events Lead to Drug Discontinuation More Commonly among Patients Who Receive Nafcillin than among Those Who Receive Oxacillin | 4.3 | 19 | Citations (PDF) |
| 115 | Clinical Outcomes of Bloodstream Infections Due to Vancomycin-Resistant Enterococcus faecium | 0.8 | 0 | Citations (PDF) |
| 116 | The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis | 2.7 | 34 | Citations (PDF) |
| 117 | Association between the Presence of Aminoglycoside-Modifying Enzymes and
<i>In Vitro</i>
Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species | 4.3 | 39 | Citations (PDF) |
| 118 | Evaluation of the
<i>In Vitro</i>
Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates | 4.3 | 83 | Citations (PDF) |
| 119 | Clinical perspectives on echinocandin resistance among Candida species | 3.5 | 63 | Citations (PDF) |
| 120 | Spontaneous fungal peritonitis: a devastating complication of cirrhosis | 3.3 | 24 | Citations (PDF) |
| 121 | Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance | 5.6 | 306 | Citations (PDF) |
| 122 | Doripenem MICs and
<i>ompK36</i>
Porin Genotypes of Sequence Type 258, KPC-Producing Klebsiella pneumoniae May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia | 4.3 | 26 | Citations (PDF) |
| 123 | Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on the
<i>In Vitro</i>
Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae | 4.3 | 111 | Citations (PDF) |
| 124 | Rate of<i>FKS</i>Mutations among Consecutive Candida Isolates Causing Bloodstream Infection | 4.3 | 49 | Citations (PDF) |
| 125 | <i>In Vitro</i>
Responses of Acinetobacter baumannii to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem | 4.3 | 39 | Citations (PDF) |
| 126 | Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance | 4.3 | 98 | Citations (PDF) |
| 127 | Epidemiology and Clinical Outcomes of Patients with Carbapenem-Resistant Klebsiella pneumoniae Bacteriuria | 4.3 | 33 | Citations (PDF) |
| 128 | KPC-Producing Klebsiella pneumoniae Strains That Harbor AAC(6′)-Ib Exhibit Intermediate Resistance to Amikacin | 4.3 | 19 | Citations (PDF) |
| 129 | Doripenem, Gentamicin, and Colistin, Alone and in Combinations, against Gentamicin-Susceptible, KPC-Producing Klebsiella pneumoniae Strains with Various
<i>ompK36</i>
Genotypes | 4.3 | 33 | Citations (PDF) |
| 130 | Candida Biofilm: Clinical Implications of Recent Advances in Research | 3.4 | 2 | Citations (PDF) |
| 131 | Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations | 4.1 | 36 | Citations (PDF) |
| 132 | Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates | 4.3 | 59 | Citations (PDF) |
| 133 | Carbapenem-Resistant Klebsiella pneumoniae Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents | 4.3 | 96 | Citations (PDF) |
| 134 | Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying
<i>FKS</i>
Mutant Candida glabrata Strains and Echinocandin Resistance | 4.3 | 54 | Citations (PDF) |
| 135 | Mutations of the
<i>ompK36</i>
Porin Gene and Promoter Impact Responses of Sequence Type 258, KPC-2-Producing Klebsiella pneumoniae Strains to Doripenem and Doripenem-Colistin | 4.3 | 85 | Citations (PDF) |
| 136 | Characterization of Porin Expression in Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae Identifies Isolates Most Susceptible to the Combination of Colistin and Carbapenems | 4.3 | 42 | Citations (PDF) |
| 137 | Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure | 4.3 | 92 | Citations (PDF) |
| 138 | Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study | 3.2 | 43 | Citations (PDF) |
| 139 | Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity | 4.3 | 110 | Citations (PDF) |
| 140 | The Presence of an
<i>FKS</i>
Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata | 4.3 | 153 | Citations (PDF) |
| 141 | The Combination of Doripenem and Colistin Is Bactericidal and Synergistic against Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae | 4.3 | 63 | Citations (PDF) |
| 142 | Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome | 1.7 | 10 | Citations (PDF) |
| 143 | Staphylococcus aureus infections in the early period after lung transplantation: Epidemiology, risk factors, and outcomes | 0.8 | 56 | Citations (PDF) |
| 144 | Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Infections among Solid Organ Transplant Recipients | 2.5 | 117 | Citations (PDF) |
| 145 | Performance of Candida Real-time Polymerase Chain Reaction, -D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis | 5.6 | 236 | Citations (PDF) |
| 146 | High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen | 1.7 | 64 | Citations (PDF) |
| 147 | Comparison of an Aspergillus Real-time Polymerase Chain Reaction Assay With Galactomannan Testing of Bronchoalvelolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis in Lung Transplant Recipients | 5.6 | 122 | Citations (PDF) |
| 148 | Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum | 4.3 | 60 | Citations (PDF) |
| 149 | Five-Minute Exposure to Caspofungin Results in Prolonged Postantifungal Effects and Eliminates the Paradoxical Growth of Candida albicans | 4.3 | 16 | Citations (PDF) |
| 150 | Posaconazole Serum Concentrations among Cardiothoracic Transplant Recipients: Factors Impacting Trough Levels and Correlation with Clinical Response to Therapy | 4.3 | 60 | Citations (PDF) |
